Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
Clinical trial NCT04425629 · TERMINATED
Trial details
- NCT number
- NCT04425629
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-16
- Primary completion
- 2022-01-21
- Enrollment
- 10078
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.